The elderly account for the majority of medical spending in many countries, raising concerns about potentially unnecessary spending, especially during the final months of life. Using a well-defined ...
DelveInsight’s, “Myocardial Infarction Pipeline Insight, 2025” report provides comprehensive insights about 30+ companies and 40+ pipeline drugs in Myocardial Infarction pipeline landscape. It covers ...
While there are therapies to aid in overall heart health, there are very few preventative therapies for heart failure after a significant heart attack, a serious condition that has a very significant ...
Although active cancer is recognised as a risk factor for increased bleeding, the specific bleeding risks associated with ...
Background The role of mineralocorticoid receptor antagonists (MRAs) in acute myocardial infarction (MI) remains ...
The world's first clinical trial to test glenzocimab as a potential new drug to improve the long-term outcomes for heart attack patients will take place in the UK. Glenzocimab is a humanised ...
In a Liv Hospital study, stem cell therapy improved heart function dramatically using MSCs and EVs, despite a blocked graft.
Myocardial infarction, or a heart attack, remains the most common cause of heart failure (HF) worldwide. Although there are treatments that aid in overall heart health, there are few preventative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback